Dr Reddy's Wegovy Generic Set for 50-60% Discounts in India

Dr Reddy's Laboratories, a leading Indian drugmaker, is preparing to launch a generic version of Novo Nordisk's blockbuster weight-loss drug Wegovy, priced competitively with discounts of 50-60% compared to the branded product. This development, announced by top executive G V Prasad, co-chairman and managing director, comes as the patent for semaglutide—the active ingredient in Wegovy—nears expiry in March, opening doors for generics in India.

Executive Insights on Pricing and Strategy

In an interview on the sidelines of the BioAsia conference in Hyderabad, G V Prasad told Reuters: "Fifty to 60% (lower than the innovator) is very comfortable." He emphasized that such pricing "is not bad on the innovator drug." Currently, Wegovy's monthly price in India ranges from 10,850 Indian rupees ($119.65) for the lowest 0.25 mg dose to 16,400 rupees for the highest 2.4 mg dose. While Prasad declined to specify an exact price for Dr Reddy's generic, he confirmed that discounts in the 50-60% range are feasible, aligning with analyst estimates for generic obesity drugs.

Why Competitive Pricing Matters for Semaglutide Access

Semaglutide, a GLP-1 receptor agonist, mimics the hormone GLP-1 to regulate blood sugar, slow gastric emptying, and reduce appetite, making it highly effective for chronic weight management. Wegovy is approved for obesity treatment in adults with a BMI of 30 or higher, or 27 with weight-related conditions. High costs have limited access, especially in price-sensitive markets like India. A 50-60% discount could make this therapy viable for millions, potentially accelerating adoption amid a global obesity epidemic affecting over 1 billion people.

India's Role in the Booming Weight-Loss Drug Market

India is emerging as a key battleground for drugmakers vying for share in the global weight-loss drug market, projected by analysts to reach $150 billion annually by the end of the decade. Dr Reddy's plans to partner with local entities for the launch and leverages sufficient production capacity to meet demand. The company aims to sell 12 million injectable semaglutide pens in the first year. However, Prasad noted the competitive landscape: "In the generic industry, everybody is going to launch, so we'll have to figure out who will get market share."

Semaglutide's Mechanism and Clinical Benefits

As a peptide therapy, semaglutide binds to GLP-1 receptors in the pancreas, brain, and gut, promoting insulin secretion, inhibiting glucagon, and signaling satiety. Clinical trials like STEP showed Wegovy users achieving 15-20% body weight loss over 68 weeks, far surpassing lifestyle interventions alone. Beyond weight loss, semaglutide offers cardiovascular benefits, reducing risks in patients with obesity-related heart disease. These outcomes underscore why generics could democratize access to metabolic health improvements.

Regulatory Milestones and Approvals

Dr Reddy's recently received approval from India's drug regulator to manufacture and sell a generic version of Ozempic—another semaglutide brand from Novo Nordisk used primarily for type 2 diabetes but often prescribed off-label for weight loss. The company is awaiting similar approval for its generic Wegovy. The semaglutide patent expiry in March will pave the way for multiple entrants, intensifying competition.

Comparing Ozempic and Wegovy Generics

Ozempic and Wegovy share the same active ingredient but differ in dosing: Ozempic maxes at 2 mg weekly for diabetes, while Wegovy escalates to 2.4 mg for obesity. Dr Reddy's generic Ozempic approval positions it well for Wegovy, potentially offering unified supply chains. Patients switching or starting should note that both require gradual titration to minimize side effects like nausea.

What This Means for Patients Considering GLP-1 Therapy

For individuals with obesity or overweight with comorbidities, Dr Reddy's generic Wegovy could lower barriers to starting semaglutide. Consult your doctor to assess eligibility—typically BMI criteria plus lifestyle efforts. Discuss titration schedules, from 0.25 mg upward, and monitor for gastrointestinal side effects, which affect 20-40% initially but often subside. Long-term use is key for sustained weight loss, with discontinuation leading to regain in most cases.

Safety profiles include risks like pancreatitis or thyroid tumors (rare), so baseline screenings are essential. Tools like Shotlee can help track symptoms, side effects, or injection schedules, ensuring better adherence and outcomes. Compared to alternatives like tirzepatide (Mounjaro/Zepbound), semaglutide offers proven efficacy at potentially lower generic costs.

Patient Guidance: Starting Semaglutide Affordably

• Eligibility Check: BMI ≥30, or ≥27 with hypertension/diabetes.
• Dosing: Weekly subcutaneous injections; start low to build tolerance.
• Cost Savings: 50-60% off branded prices could drop monthly costs below 5,000-7,000 INR.
• Monitoring: Regular weigh-ins, A1C checks; report persistent GI issues.

Broader Company Developments

Separately, Prasad revealed Dr Reddy's aims to launch a biosimilar version of cancer therapy rituximab (branded as Rituxan by Genentech and Biogen) in the United States, pending approval. The company is not planning immediate U.S. manufacturing expansion. ($1 = 90.6780 Indian rupees)

Key Takeaways

• Dr Reddy's generic Wegovy to launch post-March patent expiry at 50-60% discounts.
• G V Prasad: Pricing feasible amid $150B market growth.
• 12 million pens targeted in year one; Ozempic generic already approved.
• Enhanced access could benefit millions managing obesity with GLP-1s.

Conclusion: Actionable Insights for Metabolic Health

Dr Reddy's entry into generic Wegovy signals a shift toward affordable peptide therapy in India, preserving semaglutide's benefits while addressing cost hurdles. Patients should discuss with healthcare providers soon, especially as competition ramps up. Stay informed on approvals and track your journey for optimal results—this could be a pivotal step in global metabolic health equity.